Rabies vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MalariaHIV InfectionPlasmodium Falciparum MalariaRabies

479 competitors in Malaria

#DrugCompanyPhaseTrials

1

Rabies vaccine

Novartis

Phase 3

92

Biltricide

Bayer

Preclinical

13

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

16

IV LBH589

Novartis

Preclinical

17

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

18

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

19

RTS,S/AS01E

GSK

Preclinical

410

Malarone

Medicines for Malaria Venture

Preclinical

3Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity12 trials

Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age

Completed·Novartis·Phase 3·NCT02177032·885 enrolled

Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen

Not yet recruiting·Sinovac Biotech Co., Ltd·Phase 3·NCT07055893·390 enrolled

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05453487·360 enrolled

Show 9 more trials

Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins

Completed·QQueen Saovabha Memorial Institute·N/A·NCT01641315·75 enrolled

Safety and Immunogenicity of ID vs IM Rabies Vaccine

Not yet recruiting·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 2/3·NCT07345208·90 enrolled

Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children

Unknown status·QQueen Saovabha Memorial Institute··NCT02339896·45 enrolled

Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years

Unknown status·AAfrican Malaria Network Trust·Phase 1·NCT00703066·30 enrolled

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04019444·50 enrolled

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Completed·UUniversity of Oxford·Phase 1/2·NCT03896724·450 enrolled

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Completed·Novartis·Phase 3·NCT01466387·552 enrolled

Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania

Completed·UUniversity of Oxford·Phase 1·NCT03435874·63 enrolled

Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis

Completed·SState University of New York - Upstate Medical University·Phase 4·NCT02374814·60 enrolled

Malaria9 trials

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

Recruiting·UUniversity of Oxford·Phase 1/2·NCT05790889·480 enrolled

A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso

Completed·UUniversity of Oxford·Phase 1/2·NCT01635647·730 enrolled

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

Completed·SState University of New York - Upstate Medical University·Phase 4·NCT02564471·103 enrolled

Show 6 more trials

Efficacy of Malaria Vaccines in Kenyan Adults

Completed·UUniversity of Oxford·Phase 2·NCT01666925·120 enrolled

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Completed·GSK·Phase 2·NCT03276962·1,500 enrolled

FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali

Completed·UU.S. Army Medical Research and Development Command·Phase 1·NCT00349713·60 enrolled

R21/Matrix-M in African Children Against Clinical Malaria

Active, not recruiting·UUniversity of Oxford·Phase 3·NCT04704830·4,800 enrolled

Efficacy of Candidate Malaria Vaccines in Senegalese Adults

Completed·UUniversity of Oxford·Phase 2·NCT01658696·120 enrolled

Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT00460525·400 enrolled

Immunization3 trials

Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

Completed·CChangchun Zhuoyi Biological Co., Ltd·Phase 3·NCT05549908·1,800 enrolled

Rabies Immunization Concomitant With JEV in Children

Completed·MMahidol University·Phase 2·NCT00703521·200 enrolled

Early Rabies Vaccine Immunization in Primary School Children

Completed·PProvincial Public Health Office, Phetchabun·Phase 3·NCT01107275·703 enrolled

Immune2 trials

Rabies Immune Plasma Booster Study

Completed·CSL Behring··NCT01063140·491 enrolled

Increasing HAART-Induced Immune Restoration With Cyclosporine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00031070·40 enrolled

Pediatric2 trials

Phase I Pediatric FMP2.1/AS02A Trial in Mali

Completed·UU.S. Army Medical Research and Development Command·Phase 1·NCT00358332·100 enrolled

SYN023 With Rabies Vaccine in Healthy Pediatric Subjects

Completed·SSynermore Biologics (Suzhou) Co., Ltd.·Phase 1·NCT07342257·108 enrolled

10 more indications

Efficacy and Safety2 trials

Study to Evaluate GR1801's Efficacy and Safety

Completed·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT05846568·1,200 enrolled

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

Completed·SSynermore Biologics (Suzhou) Co., Ltd.·Phase 3·NCT04644484·1,000 enrolled

Vaccine2 trials

Purified Rabies Vaccine for Human Use (Chick-embryo Cell)

Completed·Novartis·Phase 3·NCT00345319·630 enrolled

The Protection Effect of Speeda® Rabies Vaccine for Human Use

Completed·BBeijing Center for Disease Control and Prevention·Phase 4·NCT01827917·37 enrolled

Vaccination1 trial

One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding

Unknown status·LLeiden University Medical Center·Phase 2·NCT02276625·30 enrolled

Adult Subject1 trial

A Bridging Study of the SYN023 on Healthy Adult Subjects

Completed·SSynermore Biologics (Suzhou) Co., Ltd.·Phase 1/2·NCT04495569·33 enrolled

Antibiotics1 trial

Responses to Rabies Vaccine in Adults With or Without Antibiotics

Completed·EEmory University·Phase 4·NCT03557008·37 enrolled

Immunity1 trial

Immunity Persistence After Abridged Intradermal Rabies PEP

Completed·IInstitut Pasteur·N/A·NCT04829630·180 enrolled

Monoclonal1 trial

A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody

Not yet recruiting·LLanzhou Institute of Biological Products Co., Ltd·Phase 2·NCT07445815·200 enrolled

Rift Valley Fever1 trial

Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)

Active, not recruiting·UUniversity of Oxford·Phase 2·NCT06799234·240 enrolled

Immune Response1 trial

Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults

Unknown status·QQueen Saovabha Memorial Institute·N/A·NCT02547727·40 enrolled

Rabies1 trial

A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Different Rabies Exposure Risks

Completed·SSynermore Biologics Co., Ltd.·Phase 2·NCT03961555·448 enrolled

Details

Drug Info

Related News